1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Evopoint Biosciences Co. Ltd.

Evopoint Biosciences Co. Ltd.

688837.SS
Evopoint Biosciences Co. Ltd.CN flagShanghai Stock Exchange
49.40
CNY
+5.79
- -
24.74BMarket Cap
Evopoint Biosciences Co. Ltd.
688837.SS
(Shanghai Stock Exchange)

Recent

price

49.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
FRC
0.06
- -
- -
2.54
Revenue per Share
-1.42
-1.25
-1.05
0.55
Basic EPS, GAAP
-1.78
-1.35
-1.09
0.31
Free Cash Flow per Basic Share
0.02
0.04
0.04
0.07
Dividend per Share
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
Tangible Book Value per Share
326
342
368
368
Basic Weighted Avg Shares
20
- -
- -
935
Sales/Revenue/Turnover
-2,645.69
- -
- -
22.75
Operating Margin (%)
15
18
26
40
Depreciation Expense
-463
-427
-386
203
Net Income, GAAP
- -
- -
- -
31.4
Effective Tax Rate (%)
-2,372.47
- -
- -
21.66
Profit Margin (%)
276
361
116
603
Working Capital
286
345
398
728
LT Debt
459
579
359
703
Total Equity
- -
- -
- -
11.74
Return on Invested Capital (%)
- -
- -
- -
17.64
Return on Capital (%)
- -
-82.22
-82.26
38.13
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
95.58%
Free Cash Flow
- -
- -
-128.95%
Net Income, GAAP
- -
- -
-152.48%
Sales/Revenue/Turnover
- -
- -
4,696.12%
Total Cash Common Dividend
- -
- -
47.39%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
935
2026
4
172
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-1.05
2025
- -
- -
- -
- -
0.55
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.04
2025
- -
- -
- -
- -
0.07
2026
- -
- -
- -
- -
- -
Similar Companies
Foundation Medicine, Inc. (FMI)
Biostage, Inc. (BSTG)
Tango Therapeutics, Inc. (TNGX)
Heron Therapeutics, Inc. (0J4V.L)
Inozyme Pharma, Inc. (INZY)
Plant Advanced Technologies S.A. (ALPAT.PA)
Business
Evopoint Biosciences Co., Ltd. operates as a biopharmaceutical company that offers therapies for patients with oncology and multidrug-resistant infections. The company's three core technology platforms are a Small Molecule Drug Discovery Platform, a Novel Antibody Discovery Platform, and a Targeted Protein Degradation Platform. Several of its pipeline products have advanced to Phase III clinical trials or the New Drug Application stage.